Table 2.
Characteristics of patients who underwent autologous transplant for Wilms Tumor from 1990–2013, as registered to the CIBMTR, by Disease status at transplantation.
| Variable | In remission | Disease present | Missing |
|---|---|---|---|
| Number of patients | 158 | 62 | 33 |
| Region of center | |||
| US | 129 (82) | 49 (79) | 23 (70) |
| Canada | 11 (7) | 6 (10) | 1 (3) |
| International | 18 (11) | 7 (11) | 9 (27) |
| Age at diagnosis, years, median (range) | 5 (<1–21) | 4 (<1–20) | 4 (<1–19) |
| Age at diagnosis | |||
| 0–4 | 90 (57) | 39 (63) | 18 (55) |
| 5–9 | 55 (35) | 17 (27) | 12 (36) |
| 10+ | 13 (8) | 6 (10) | 3 (9) |
| Age at transplant, years, median (range) | 7 (2–23) | 6 (2–21) | 7 (1–21) |
| Age at transplant | |||
| 0–4 | 37 (23) | 24 (39) | 8 (24) |
| 5–9 | 91 (58) | 25 (40) | 20 (61) |
| 10+ | 30 (19) | 13 (21) | 5 (15) |
| Gender | |||
| Male | 66 (42) | 34 (55) | 16 (48) |
| Female | 92 (58) | 27 (44) | 16 (48) |
| Missing | 0 | 1 (2) | 1 (3) |
| Disease status | |||
| CR2 | 85 (54) | 0 | 0 |
| CR3+ | 21 (13) | 0 | 0 |
| CR unknown * | 20 (13) | 0 | 0 |
| REL1 | 0 | 28 (45) | 0 |
| REL2 | 0 | 5 (8) | 0 |
| REL3 | 0 | 3 (5) | 0 |
| REL unknown | 0 | 8 (13) | 0 |
| Progression | 0 | 9 (15) | 0 |
| Stable disease | 0 | 9 (15) | 0 |
| Partial response * | 32 (20) | 0 | 0 |
| Missing | 0 | 0 | 33 |
| Time from diagnosis to transplant, months (continuous) | 18 (5–129) | 17 (5–208) | 17 (6–113) |
| Time from diagnosis to transplant, months (categorical) | |||
| < 12 | 22 (14) | 17 (27) | 12 (36) |
| 12–18 | 51 (32) | 17 (27) | 5 (15) |
| ≥ 18 | 85 (54) | 28 (45) | 16 (48) |
| Graft type | |||
| BM | 23 (15) | 21 (34) | 10 (30) |
| PBSC | 133 (84) | 40 (65) | 22 (67) |
| Missing | 2 (1) | 1 (2) | 1 (3) |
| Regimen groups ** | |||
| Alkylating agents | 89 (56) | 39 (63) | 14 (42) |
| Platinum agents | 55 (35) | 15 (24) | 5 (15) |
| Missing | 14 (9) | 8 (13) | 14 (42) |
| Years of transplant | |||
| 1990–1994 | 10 (6) | 15 (24) | 8 (24) |
| 1995–1999 | 34 (22) | 20 (32) | 13 (39) |
| 2000–2004 | 32 (20) | 13 (21) | 7 (21) |
| 2005–2013 | 82 (52) | 14 (23) | 5 (15) |
| Follow-up of survivors, months, median (range) | 49 (1–241) | 73 (1–239) | 33 (1–152) |
Abbreviations: CR = Complete remission, REL = Relapse, BM = Bone marrow, PBSC = Peripheral Blood Stem Cells, CY = Cyclophosphamide, LPAM = Melphalan, BU = Busulfan, THIO = Thiotepa, CARB = Carboplatinum.
*
Determined patients not in CR1 or PR1 based on duration of time from diagnosis to transplant.
**
Alkylating agents are defined as CY+LPAM, BU+CY, BU+LPAM, LPAM, CY+THIO, CY;
Platinum agents are defined as CARB+LPAM, CY+CARB, CARB.